{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:19:06Z","timestamp":1791206346516,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.ejca.2005.11.040","type":"journal-article","created":{"date-parts":[[2006,7,6]],"date-time":"2006-07-06T23:08:06Z","timestamp":1152227286000},"page":"1591-1600","source":"Crossref","is-referenced-by-count":30,"title":["State of the art therapy in multiple myeloma and future perspectives"],"prefix":"10.1016","volume":"42","author":[{"given":"Ulrich","family":"Denz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2005.11.040_bib1","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with haematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.040_bib2","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/cncr.20294","article-title":"Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma","volume":"100","author":"Anagnostopoulos","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2005.11.040_bib3","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.040_bib4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1702167","volume":"25","author":"Desikan","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2005.11.040_bib5","doi-asserted-by":"crossref","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749\u2013757.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"10.1016\/j.ejca.2005.11.040_bib6","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.11.040_bib7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.bmt.1700705","article-title":"Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumour and non-Hodgkin\u2019s Lymphoma patients after combination chemotherapy and G-CSF","volume":"19","author":"Engelhardt","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2005.11.040_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002770100289","article-title":"Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation","volume":"80","author":"Engelhardt","year":"2001","journal-title":"Ann Haematol"},{"key":"10.1016\/j.ejca.2005.11.040_bib9","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.1999.17.7.2160","article-title":"High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection","volume":"17","author":"Engelhardt","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.11.040_bib10","unstructured":"Engelhardt M, Berger D, Mertelsmann R, editors. www.cancer.de. Das Blaue Buch GCP-m@nual 5.1., 2005."},{"key":"10.1016\/j.ejca.2005.11.040_bib11","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib12","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J Support Oncol"},{"issue":"suppl","key":"10.1016\/j.ejca.2005.11.040_bib13","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1182\/blood.V106.11.5129.5129","article-title":"Dose reduction of Thalidomide in multiple myeloma: a feasible option without reducing of efficacy","volume":"106","author":"Haas","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.thj.6200322","article-title":"Strategies to improve the outcome of stem cell transplantation in multiple myeloma","volume":"5","author":"Catley","year":"2004","journal-title":"Haematol J"},{"key":"10.1016\/j.ejca.2005.11.040_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.040_bib16","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.bmt.1704192","article-title":"A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma","volume":"32","author":"Einsele","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2005.11.040_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00277-005-0040-x","article-title":"Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single center analysis over a 12 year period","volume":"85","author":"Haas","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2005.11.040_bib19","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib20","first-page":"560","article-title":"Single versus Tandem Autologous Transplants in Multiple Myeloma: Italian Experience [abstract]","volume":"4","author":"Cavo","year":"2003","journal-title":"Haematol J"},{"key":"10.1016\/j.ejca.2005.11.040_bib21","first-page":"559","article-title":"Intensive versus Double Intensive Therapy in Untreated Multiple Myeloma: Updated Analysis of the Prospective Phase III Study Hovon 24-MM [abstract]","volume":"4","author":"Sonneveld","year":"2003","journal-title":"Haematol J"},{"key":"10.1016\/j.ejca.2005.11.040_bib22","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bmt.1704713","article-title":"Extramedullary vs medullary relapse after autologous or allogeneic haematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome","volume":"34","author":"Zeiser","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2005.11.040_bib23","first-page":"266a","article-title":"Addition of Bortezomib to high dose Melphalan (Vel-Mel) as an effective conditioning regimen with autologous stem cell support in Multiple Myeloma","volume":";104","author":"Talamo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib24","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.040_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.11.040_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2005.11.040_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.seminoncol.2004.10.016","article-title":"Clinical update: novel targets in multiple myeloma","volume":"31","author":"Anderson","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2005.11.040_bib28","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.040_bib29","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.leu.2403723","article-title":"Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient","volume":"19","author":"Engelhardt","year":"2005","journal-title":"Leukaemia"},{"key":"10.1016\/j.ejca.2005.11.040_bib30","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.040_bib31","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.040_bib32","first-page":"98a","article-title":"A phase 2 study ob Bortezomib as first-line therapy in patients with multiple myeloma","volume":"104","author":"Jagganath","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib33","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatroy drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed muliple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib34","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (REV\/DEX) for newly diagnosed myeloma. Blood 2005 (First Edition Paper, prepublished online August 23).","DOI":"10.1182\/blood-2005-07-2817"},{"key":"10.1016\/j.ejca.2005.11.040_bib35","first-page":"160","article-title":"Evaluating oral lenalidomide (Revlimid) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma (abstract)","volume":"90","author":"Dimopoulos","year":"2005","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2005.11.040_bib36","first-page":"13","article-title":"Treatment decision-making in elderly with newly diagnosed acute myeloid leukaemia","volume":"83","author":"Deschler","year":"2004","journal-title":"Annals Haematol"},{"key":"10.1016\/j.ejca.2005.11.040_bib37","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood.V104.11.2421.2421","article-title":"A phase II study of Velcade, Doxil in combination with low-dose thalidomide as salvage therapy for patients with relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia: encouraging preliminary results","volume":"104","author":"Chanan-Khan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib38","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdi125","article-title":"Dutch-Belgian Haemato-Oncology Cooperative Group HOVON Interferon-alpha as maintenance therapy in patients with multiple myeloma","volume":"16","author":"Schaar","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2005.11.040_bib39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1365-2141.1998.00795.x","article-title":"A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results","volume":"102","author":"Cunningham","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.11.040_bib40","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib41","doi-asserted-by":"crossref","unstructured":"Attal M, Harousseau JL, Leyvraz S, et al. Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma: First Analysis of a Prospective Randomized Study of the Intergroupe Francophone du Myelome (IFM 99 02). ASH 2004: 535.","DOI":"10.1182\/blood.V104.11.535.535"},{"key":"10.1016\/j.ejca.2005.11.040_bib42","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.11.040_bib43","doi-asserted-by":"crossref","unstructured":"Michael W, Schuster and Joanne M. Dymek. Oral Cavity Avascular Bone Necrosis - a Newly Recognized Complication of Intravenous (IV) Bisphosphonate Therapy in Cancer Patients. Blood, 104, 4905.","DOI":"10.1182\/blood.V104.11.4905.4905"},{"key":"10.1016\/j.ejca.2005.11.040_bib44","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V104.11.756.756","article-title":"Osteonecrosis of the Jaws in Myeloma: Time Dependent Correlation with Aredia\u00ae and Zometa\u00ae Use","volume":"104","author":"Durie","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib45","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ejca.2005.11.040_bib46","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","article-title":"Bisphosphanates and oral cavity avascular bone necrosis","volume":"21","author":"Migliorati","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.11.040_bib47","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ejca.2005.11.040_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Maerevoet","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.040_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2005.11.040_bib50","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/JCO.2002.07.177","article-title":"American Society of Clinical Oncology. American Society of Haematology. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Haematology","volume":"20","author":"Rizzo","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.11.040_bib51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMcp010518","article-title":"Clinical practice. Long-term care after haematopoietic-cell transplantation in adults","volume":"347","author":"Antin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.040_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-004-0939-7","article-title":"Epidemiology of non-Hodgkin\u2019s lymphoma (NHL): trends, geographic distribution, and etiology","volume":"84","author":"Muller","year":"2005","journal-title":"Ann Haematol"},{"key":"10.1016\/j.ejca.2005.11.040_bib53","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00277-005-1097-2","article-title":"Occurrence of multiple myeloma 13 years after Hodgkin\u2019s disease: chance or consequence?","volume":"84","author":"Strobel","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2005.11.040_bib54","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1158\/0008-5472.CAN-05-0298","article-title":"MicroRNA biogenesis and cancer","volume":"65","author":"Gregory","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2005.11.040_bib55","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bmt.1703715","article-title":"Transplantation as salvage therapy for high-risk patients with myeloma in relapse","volume":"30","author":"Lee","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2005.11.040_bib56","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood.V85.11.3077.bloodjournal85113077","article-title":"Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma","volume":"85","author":"Harousseau","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib57","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood.V79.5.1130.1130","article-title":"Intensive combined therapy for previously untreated aggressive myeloma","volume":"79","author":"Attal","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib58","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.V79.11.2827.bloodjournal79112827","article-title":"Double-intensive therapy in high-risk multiple myeloma","volume":"79","author":"Harousseau","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib59","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib60","first-page":"7","article-title":"Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study","volume":"95","author":"Lenhoff","year":"2000","journal-title":"Nordic Myeloma Study Group. Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.bmt.1701062","article-title":"Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Haematopoyetico-GETH) and PETHAEMA","volume":"21","author":"Alegre","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2005.11.040_bib62","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation","volume":"88","author":"Bjorkstrand","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib63","first-page":"844","article-title":"Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo","volume":"84","author":"Majolino","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2005.11.040_bib64","doi-asserted-by":"crossref","unstructured":"Zangari M, Barlogie B, Hollmig K, et al. Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM). Blood, 104, 1480.","DOI":"10.1182\/blood.V104.11.1480.1480"},{"key":"10.1016\/j.ejca.2005.11.040_bib65","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood.V104.11.1478.1478","article-title":"PAD Combination Therapy (PS-341\/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma","volume":"104","author":"Cavenagh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib66","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumour activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.040_bib67","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.thj.6200326","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma","volume":"5","author":"Dimopoulos","year":"2004","journal-title":"Haematol J"},{"key":"10.1016\/j.ejca.2005.11.040_bib68","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.20382","article-title":"Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma","volume":"79","author":"Wang","year":"2005","journal-title":"AmJ Haematol"},{"key":"10.1016\/j.ejca.2005.11.040_bib69","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib70","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V104.11.331.331","article-title":"Combination Therapy with CC-5013 (Lenalidomide; RevlimidTM) Plus Dexamethasone (Rev\/Dex) for Newly Diagnosed Myeloma (MM)","volume":"104","author":"Rajkumar","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib71","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2141.2004.04941.x","article-title":"Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma","volume":"125","author":"Hussein","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.11.040_bib72","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1182\/blood.V104.11.2398.2398","article-title":"A Phase I\/II Multicenter, Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) in Patients with Relapsed or Refractory Multiple Myeloma","volume":"104","author":"Berenson","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib73","first-page":"2564","article-title":"Novel therapy with 2-methoxyestradiol (2-ME) for relapsed and plateau phase multiple myeloma","volume":"102","author":"Rajkumar","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib74","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1182\/blood.V104.11.1503.1503","article-title":"Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed\/Refractory Multiple Myeloma (MM)","volume":"104","author":"Richardson","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib75","first-page":"2533","article-title":"Phase I\/II trial of oblimersen sodium (G3139), dexamethasone (Dex) and thalidomide (Thal) in patients with relapsed multiple myeloma","volume":"102","author":"Badros","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.040_bib76","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1158\/1078-0432.CCR-0221-3","article-title":"Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma","volume":"10","author":"Zangari","year":"2004","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906003248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906003248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T08:56:20Z","timestamp":1627548980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804906003248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0959804906003248"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2005.11.040","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}